-
Synopsis: The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 to about 8 times as high as the hazard ratios associated with other independent clinical and pathological risk factors, including axillary node status.
-
The Womens Angiographic Vitamin and Estrogen (WAVE) Trial was a randomized, controlled secondary prevention study. This study enrolled 423 postmenopausal women with coronary atherosclerosis already established at baseline by angiography.
-
After years of legal wrangling, the FDA has approved loratadine (Claritin, Schering-Plough) as an over-the-counter (OTC) product for the treatment of seasonal rhinitis.
-
-
-
Synopsis: The Nurses Health Study reports an increased incidence of breast cancer with daily alcohol consumption, hormone therapy, and an additive effect with greater drinking.
-
This study suggests that high-dose rofecoxib may increase the risk of cardiovascular events.
-
-
The FDA has approved the first generic version of AstraZeneca plcs blockbuster drug, omeprazole (Prilosec).
-
The 12-lead ECG and accompanying rhythm strip in the Figure were obtained from an 84-year-old man who presented to the Emergency Department with acute dyspnea from pneumonia and heart failure. Can you account for the relatively slow heart rate despite his acute shortness of breath?